Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 226.40 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 45 46 Next > The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB) July 19, 2024 From The Law Offices of Frank R. Cruz Via Business Wire BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm July 19, 2024 From The Schall Law Firm Via Business Wire SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen July 18, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Key Takeaways From Biogen Analyst Ratings July 12, 2024 Via Benzinga Will BIOGEN INC breakout? July 11, 2024 Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent? Via Chartmill Forecasting The Future: 19 Analyst Projections For Biogen June 26, 2024 Via Benzinga Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm July 16, 2024 From Schall Law Via GlobeNewswire Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' July 15, 2024 Via Benzinga Topics Bankruptcy Exposures Financial Legal BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc. July 15, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split July 15, 2024 Revenue is climbing at these two drug companies -- and the trend should continue. Via The Motley Fool Did Eli Lilly Just Get a Leg Up on Novo Nordisk? July 13, 2024 Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk. Via The Motley Fool DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen July 12, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm July 11, 2024 From Kirby McInerney LLP Via GlobeNewswire BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm July 11, 2024 From The Schall Law Firm Via Business Wire BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm July 09, 2024 From Schall Law Via GlobeNewswire BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline July 08, 2024 From Bernstein Liebhard LLP Via GlobeNewswire 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. Via InvestorPlace SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen July 04, 2024 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options From Faruqi & Faruqi LLP Via GlobeNewswire Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst July 03, 2024 The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... Via Benzinga Exposures Product Safety BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP July 02, 2024 From Robbins LLP Via GlobeNewswire Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai July 02, 2024 The company is on deck to rival Biogen and Eisai's Leqembi. Via Investor's Business Daily BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm July 02, 2024 From Schall Law Via GlobeNewswire Biogen Completes Acquisition of Human Immunology Biosciences July 02, 2024 From Biogen Inc. Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm July 01, 2024 From Bragar Eagel & Squire Via GlobeNewswire BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline July 01, 2024 From Bernstein Liebhard LLP Via GlobeNewswire This Is Massive News for Eli Lilly Investors June 29, 2024 A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate. Via The Motley Fool ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen June 28, 2024 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options From Faruqi & Faruqi LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm June 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China June 27, 2024 China is the Third Country to Launch LEQEMBI Following the United States and Japan From Biogen Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 45 46 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.